Evidence map›Paper›PMID 27822662›Full record

ArticleMolecular and cellular biochemistry2017

miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL.

Xia Cui, Qingyan Li, Yukai He

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular and cellular biochemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Article
  3. Oncogenic role ofAutophagy · 2021
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Xia CuiDepartment of Hepatopathy, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng, 252000, China.
Qingyan LiDepartment of Hepatopathy, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng, 252000, China.
Yukai HeDepartment of Hepatopathy, Liaocheng People's Hospital, 67 Dongchang West Road, Liaocheng, 252000, China. Heyukai94210899@163.com.
Liaocheng People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Altered microRNA expression is associated with tumor proliferation, metastasis, and tumorigenesis. In this study, we studied the role of miR-3117 in hepatocellular carcinoma (HCC) cell proliferation and found that miR-3117 was upregulated in HCC tissues and cells. MTT assay, soft agar growth assay, BrdU assay, and cell cycle assay revealed that miR-3117 overexpression promoted HCC HepG2 cell proliferation and that knockdown of miR-3117 suppressed HepG2 proliferation. Mechanism analysis suggested PH domain and leucine-rich repeat protein phosphatase-like (PHLPPL) as the target of miR-3117. Luciferase reporter assay suggested that miR-3117 directly binds to the 3'UTR of PHLPPL. Double knockdown of miR-3117 and PHLPPL copied the phenotypes caused by miR-3117 overexpression, suggesting that miR-3117 contributes to the proliferation of HepG2 by targeting PHLPPL. Our study provided a target for HCC therapy.

Indexed as

Cell ProliferationCarcinoma, HepatocellularHep G2 CellsHumansLiver NeoplasmsMicroRNAsNeoplasm ProteinsPhosphoprotein PhosphatasesRNA, NeoplasmMicroRNAsNeoplasm ProteinsPHLPP2 protein, humanPhosphoprotein PhosphatasesRNA, NeoplasmHepatocellular carcinomamicroRNAmiR-3117PHLPPL

Identifiers

PMID27822662
OpenAlexW2551507561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.